BeyondSpring Inc. (BYSI): Submission of Matters to a Vote of Security Holders

BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. (a) BeyondSpring Inc. (the “Company”) held its 2026 annual meeting of shareholders on October 13, 2026. A total of 20,905,921 of the Company’s ordinary shares were present or represented by proxy at the meeting, repr

Event · Shareholder vote
Original reporting
Published Oct 13, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$BYSI
Neutral
high confidence
Mentioned
$BYSI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BYSINeutralLow
01

Why it matters

The filing is a standard corporate governance disclosure with limited immediate trading relevance.

02

Market read

Low relevance; routine corporate action with minimal price impact.

03

What to watch

Potential future audit findings could affect earnings quality, but no immediate impact is evident.

Relevance 6/10Novelty 5/10Timing: post‑market filing

Background

BeyondSpring Inc. filed a Form 8‑K to disclose the results of its 2026 annual shareholder meeting, including the ratification of its independent auditor.

Company-level read

Ticker impact

$BYSINeutralHigh confidence
Context

SEC 8‑K reports shareholders ratified CBIZ CPAs as independent auditor for FY 2026.

Expected impact

likely neutral as the matter is routine and does not change fundamentals

Evidence & confidence

The vote confirms the auditor appointment; such filings historically have negligible price impact.

Market effects

None; auditor appointments are company‑specific and do not affect the broader sector.

None; the filing is limited to BeyondSpring Inc. shareholders.

None; no broader market relevance.

Counterpoint

If investors view auditor changes as a signal of upcoming financial scrutiny, a slight negative bias could emerge.

Key entities

  • BeyondSpring Inc.

    Issuer of the 8‑K filing.

  • CBIZ CPAs P.C.

    Independent registered public accounting firm appointed for FY 2026.

Related articles

$BYSIHigh

BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update FDA Fast Track Designation for Plinabulin plus docetaxel marks key regulatory milestone in DUBLIN-4 study population of Post-ICI Non-Squamous NSCLC with no actionable genomic alte

$BYSILow

BeyondSpring Inc. (BYSI): Completion of Acquisition or Disposition of Assets

BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On September 28, 2026, BeyondSpring Inc. (“BYSI” or the “Company”) entered into a Share Purchase and Collaboration Agreement (the “Agreement”) with Dalian Wanchunbulin Pharmaceuticals Ltd. (“Bulin”), a

$BYSIMed

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibito

$BYSIMedAI 8/10

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

BeyondSpring Inc. (NASDAQ: BYSI) announced a leadership transition effective July 1, 2026. Dr. Lan Huang will remain Chairman; Dr. Jiangwen (Jen) Majeti becomes Vice Chairman; Min Qiu is appointed CEO to execute the confirmatory DUBLIN-4 Phase 3 trial of Plinabulin plus docetaxel; and Na Li becomes CFO to strengthen the company’s financial position and capital markets engagement.